Le Lézard
Classified in: Health
Subject: SVY

Global $273 Bn Active Pharmaceutical Ingredient Market to 2026 Featuring TEVA Pharma & Dr. Reddys

DUBLIN, Feb. 14, 2019 /PRNewswire/ --

The "Global Active Pharmaceutical Ingredient Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The active pharmaceutical ingredient market was valued at US$ 152.6 Bn in 2017 and expected to reach US$ 273.5 Mn by 2026 at a CAGR of 6.7 % during the forecast period from 2018 to 2026.

The global active pharmaceutical ingredient (API) market shows fruitful growth during the forecast period from 2018 to 2026. The API is the active part of any drug that delivers its reaction. Many times a drug may contain few APIs and the reaction to a specific medication will rely upon the prescription of the dosage pattern, which changes from individual to individual. For instance, combination therapeutic treatments have various dynamic active ingredients to treat different side effects. TEVA Pharmaceuticals is one of the leading manufacturers of APIs in the global market having a vast portfolio of API products of around 300 APIs. Dr. Reddy's is also a leading API maker using more than 60 APIs currently.

North America to contribute maximum revenue share in the global active pharmaceutical ingredient market attributed to rising chronic diseases, higher adoption of prescribed drugs, demand for specialty drugs & biologics, increasing awareness, and rise in R&D for new drug formulations and development. In the current scenario, manufacturers present in the U.S. and Europe region are expanding their manufacturing capacity for APIs in the developing nations such as in India and China to cut expenses. This has made noteworthy changes in how these drugs are regulated, with more specific guidelines and regulations. For example, presently AstraZeneca Plc produce only 15% of their APIs in the U.S.

However, there are plans to end that small ratio and outsource all the manufacturing assembly in the Asia Pacific and Latin America market. Increase in healthcare spending is a global phenomenon, and this directly benefited the generics API market in recent years in the developing nations due to high demand and ease of access. However, the cost of enhancing process outline, higher cost of specialty API drugs, and stringent approvals regulations may act as a restraining factor to the overall development of the API market.

Improvement of new inventive API's and inorganic development through mergers and partnerships with smaller organizations additionally support the API market in the developing nations. Adoption of branded generic drugs & medications is growing exponentially in developing economies, for example, in India and China. In addition, rising utilization of specialty drugs expected to increase the pharmaceutical spending around the world.

Increase in demand for advanced therapeutics for treatment of alarming diseases, rising prevalence for chronic diseases and lifestyle diseases globally along with increasing purchasing power, beneficiary schemes for reimbursement are various factors fueling the demand for active pharmaceutical ingredient market in near future.

Key Market Movements:

Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

Chapter 2. Executive Summary
2.1. Global Active Pharmaceutical Ingredient Market Portraiture
2.2. Global Active Pharmaceutical Ingredient Market, By API Type, 2017 (US$ Mn)
2.3. Global Active Pharmaceutical Ingredient Market, By Drug Type, 2017 (US$ Mn)
2.4. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2017 (US$ Mn)
2.5. Global Active Pharmaceutical Ingredient Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Active Pharmaceutical Ingredient Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Active Pharmaceutical Ingredient Technologies: Future Trends
3.3. Current Scenario: Strategies Used for Shifting Manufacturing Plants Internationally
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Active Pharmaceutical Ingredient Market, by API Type, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Synthetic Chemical API
4.3. Biological API

Chapter 5. Global Active Pharmaceutical Ingredient Market, by Drug Type, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. Branded Drugs
5.3. Generic Drugs
5.4. OTC Drugs

Chapter 6. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 - 2026 (US$)
6.1. Overview
6.2. Contract Manufacturers
6.3. Captive Manufacturers

Chapter 7. Global Active Pharmaceutical Ingredient Market, by Geography, 2016 - 2026 (US$ Mn)

Chapter 8. Company Profiles
8.1. Teva Pharmaceutical Industries Ltd.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Pfizer, Inc.
8.3. Sanofi
8.4. Boehringer Ingelheim
8.5. Novartis International AG
8.6. Bristol-Myers Squibb
8.7. Eli Lilly and Company
8.8. GlaxoSmithKline plc
8.9. Merck & Co., Inc.
8.10. AbbVie Inc.
8.11. Lonza Group

For more information about this report visit https://www.researchandmarkets.com/research/rvfm5l/global_273_bn?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

These press releases may also interest you

at 15:45
The "Animal Health Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering. The global animal health market was worth more than US$ 44 Billion in 2018...

at 15:43
Children's Minnesota received re-verification by the American College Surgeons (ACS) as a Level I pediatric trauma center on its Minneapolis campus, the highest level offered by the organization's Committee on Trauma. The renewal of this key...

at 15:39
The Angiogenesis Foundation announced today its President and CEO Dr. William Li's highly-praised book, EAT TO BEAT DISEASE: The New Science of How Your Body Can Heal Itself (Grand Central Publishing) has been listed as a New York Times Bestseller in...

at 15:38
Today, Exer Urgent Care opened a stunning medical center in Westlake Village, Calif. located near Thousand Oaks Blvd and CA-101 Highway.  The rapidly-expanding healthcare startup based in Los Angeles staffs each of its 11 facilities with ER doctors...

at 15:28
CollPlant , a regenerative medicine company, today announced the publication of a study titled, "Bone Repair with a Receptor Optimized BMP-2/6/Activin Chimera Delivered In a Novel Ceramic/rhCollagen Matrix is Superior to BMP-2" in the April issue of...

at 15:20
With nearly one in five adolescents bullied across the nation, today, STOMP Out Bullyingtm announces a first-of-its-kind AI platform, Emma, designed to help reduce bullying. Developed with consultation from Dr. Jeff Gardere, one of the most widely...

News published on 14 february 2019 at 07:30 and distributed by: